141 related articles for article (PubMed ID: 36877872)
1. Successful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy.
Srinivasan D; Gottlieb A
J Drugs Dermatol; 2023 Mar; 22(3):297-299. PubMed ID: 36877872
[TBL] [Abstract][Full Text] [Related]
2. Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Bang AS; Said JT; Hirner J; Rana J; Pugliese S; Wang JY; Zaba L; Zhao L; Doan L; Smith J; Kwong BY
Support Care Cancer; 2024 May; 32(6):354. PubMed ID: 38750379
[TBL] [Abstract][Full Text] [Related]
3. Erythema dyschromicum perstans: response to dapsone therapy.
Bahadir S; Cobanoglu U; Cimsit G; Yayli S; Alpay K
Int J Dermatol; 2004 Mar; 43(3):220-2. PubMed ID: 15009398
[TBL] [Abstract][Full Text] [Related]
4. Erythema dyschromicum perstans and lichen planus.
Naidorf KF; Cohen SR
Arch Dermatol; 1982 Sep; 118(9):683-5. PubMed ID: 7114873
[TBL] [Abstract][Full Text] [Related]
5. Improvement of erythema dyschromicum perstans using a combination of the 1,550-nm erbium-doped fractionated laser and topical tacrolimus ointment.
Wolfshohl JA; Geddes ER; Stout AB; Friedman PM
Lasers Surg Med; 2017 Jan; 49(1):60-62. PubMed ID: 27552666
[TBL] [Abstract][Full Text] [Related]
6. Erythema dyschromicum perstans.
Tlougan BE; Gonzalez ME; Mandal RV; Kundu RV; Skopicki D
Dermatol Online J; 2010 Nov; 16(11):17. PubMed ID: 21163168
[TBL] [Abstract][Full Text] [Related]
7. Erythema dyschromicum perstans: A case report and systematic review of histologic presentation and treatment.
Leung N; Oliveira M; Selim MA; McKinley-Grant L; Lesesky E
Int J Womens Dermatol; 2018 Dec; 4(4):216-222. PubMed ID: 30627620
[TBL] [Abstract][Full Text] [Related]
8. Erythema dyschromicum perstans: a case report and review.
Osswald SS; Proffer LH; Sartori CR
Cutis; 2001 Jul; 68(1):25-8. PubMed ID: 11480143
[TBL] [Abstract][Full Text] [Related]
9. Erythema Dyschromicum Perstans: Response to Topical Tacrolimus.
Mahajan VK; Chauhan PS; Mehta KS; Sharma AL
Indian J Dermatol; 2015; 60(5):525. PubMed ID: 26538750
[TBL] [Abstract][Full Text] [Related]
10. Erythema dyschromicum perstans in early childhood.
Lee SJ; Chung KY
J Dermatol; 1999 Feb; 26(2):119-21. PubMed ID: 10091483
[TBL] [Abstract][Full Text] [Related]
11. Erythema dyschromicum perstans in a Caucasian pediatric patient.
Tisack AM; Huggins RH; Lim HW
J Drugs Dermatol; 2013 Jul; 12(7):819-20. PubMed ID: 23884499
[TBL] [Abstract][Full Text] [Related]
12. Erythema dyschromicum perstans in a Japanese child.
Oiso N; Tsuruta D; Imanishi H; Kobayashi H; Kawada A
Pediatr Dermatol; 2012; 29(5):637-40. PubMed ID: 22066655
[TBL] [Abstract][Full Text] [Related]
13. Clinical and histological aspect of erythema dyschromicum perstans in Korea: A review of 68 cases.
Chang SE; Kim HW; Shin JM; Lee JH; Na JI; Roh MR; Lee JH; Lee GY; Ko JY
J Dermatol; 2015 Nov; 42(11):1053-7. PubMed ID: 26118942
[TBL] [Abstract][Full Text] [Related]
14. Erythema Dyschromicum Perstans: Identical to Ashy Dermatosis or Not?
Numata T; Harada K; Tsuboi R; Mitsuhashi Y
Case Rep Dermatol; 2015; 7(2):146-50. PubMed ID: 26351421
[TBL] [Abstract][Full Text] [Related]
15. Involvement of cell adhesion and activation molecules in the pathogenesis of erythema dyschromicum perstans (ashy dermatitis). The effect of clofazimine therapy.
Baranda L; Torres-Alvarez B; Cortes-Franco R; Moncada B; Portales-Perez DP; Gonzalez-Amaro R
Arch Dermatol; 1997 Mar; 133(3):325-9. PubMed ID: 9080892
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of erythema dyschromicum perstans and vitiligo: a case report and review of the literature.
Tamer F
Acta Dermatovenerol Alp Pannonica Adriat; 2016 Dec; 25(4):77-78. PubMed ID: 28006880
[TBL] [Abstract][Full Text] [Related]
17. Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
Mariano M; Donati P; Cameli N; Pigliacelli F; Morrone A; Cristaudo A
J Breast Cancer; 2021 Feb; 24(1):117-121. PubMed ID: 33634626
[TBL] [Abstract][Full Text] [Related]
18. Erythema dyschromicum perstans: report of a new case and critical review of the literature.
Combemale P; Faisant M; Guennoc B; Dupin M; Heyraud JD
J Dermatol; 1998 Nov; 25(11):747-53. PubMed ID: 9863289
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial with clofazimine for treating erythema dyschromicum perstans. Evaluation of cell-mediated immunity.
Piquero-Martín J; Pérez-Alfonzo R; Abrusci V; Briceño L; Gross A; Mosca W; Tapia F; Convit J
Int J Dermatol; 1989 Apr; 28(3):198-200. PubMed ID: 2785092
[TBL] [Abstract][Full Text] [Related]
20. Erythema dyschromicum perstans in children: a report of 14 cases.
Torrelo A; Zaballos P; Colmenero I; Mediero IG; de Prada I; Zambrano A
J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):422-6. PubMed ID: 15987286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
